Peri-Infusional Adverse Reactions to Rituximab in Mexican Patients with Rheumatoid Arthritis
Latin american journal of clinical sciences and medical technology · 2019
DOI: 10.34141/ljcs1446110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Latin american journal of clinical sciences and medical technology, 2019. Verfasst von Teresa Arredondo-Garza und 10 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The treatment of rheumatoid arthritis (RA) has significantly improved since the introduction of biologics like rituximab. Rituximab achieves selective B lymphocyte depletion and, thereby, reduce inflammation. It has adverse reactions related to the immunogenic response.
Objective
The aim of this study was to evaluate the frequency and severity of rituximab adverse reactions in Mexican patients with RA.
Methods
A prospective, observational, descriptive, open-labeled, multicenter cohort study of intensive pharmacovigilance was conducted during 17 months in 10 hospitals. We included 335 adult patients with RA, 26 male an 309 female. They received two doses of rituximab (1000 mg) on days 1 and 15 in combination with methotrexate. Adverse reactions were graded according to the National Cancer Institute (NCI) scale and causality was established with the Naranjo algorithm. Infusions were classified as fast (0 to 180 minutes) and slow (> 181 minutes). The first and second infusions were compared.
Results
The total number of infusion episodes recorded was 631 and 36 adverse reactions were informed in 24 patients (7.1 %). There were no differences between the variances of the first and second infusions. All the adverse reactions were considered mild to moderate (NCI Scale). According to Naranjo algorithm, the adverse reactions to rituximab were possible or probable. The infusion speed did not have an influence on the adverse reactions; whereas the incident rate was lower than that reported by other authors.
Conclusions
Rituximab has a favorable safety profile in Mexican patients.
Zitieren
APA
Arredondo-Garza, T., Majluf-Cruz, A., Irazoque-Palazuelos, F., Rivas-Jiménez, M. D. L. L., Martínez, A., Reyes-Patatuchi, R., Mariscal-Ramírez, I., López-Villanueva, R. F., Gordillo-Huerta, V., Loaiza-Cárdenas, C., & Terán-Estrada, L. (2019). Peri-Infusional Adverse Reactions to Rituximab in Mexican Patients with Rheumatoid Arthritis. Latin american journal of clinical sciences and medical technology. https://doi.org/10.34141/ljcs1446110
Vancouver
Arredondo-Garza T, Majluf-Cruz A, Irazoque-Palazuelos F, Rivas-Jiménez MDLL, Martínez A, Reyes-Patatuchi R, et al. Peri-Infusional Adverse Reactions to Rituximab in Mexican Patients with Rheumatoid Arthritis. Latin american journal of clinical sciences and medical technology. 2019. doi:10.34141/ljcs1446110
BibTeX
@article{ArredondoGarza2019,
author = {Arredondo-Garza, Teresa and Majluf-Cruz, Abraham and Irazoque-Palazuelos, Fedra and Rivas-Jiménez, María de la Luz and Martínez, Alejandro and Reyes-Patatuchi, Roberto and Mariscal-Ramírez, Ignacio and López-Villanueva, Ricardo Francisco and Gordillo-Huerta, Vanesa and Loaiza-Cárdenas, Carlos and Terán-Estrada, Leobardo},
title = {Peri-Infusional Adverse Reactions to Rituximab in Mexican Patients with Rheumatoid Arthritis},
journal = {Latin american journal of clinical sciences and medical technology},
year = {2019},
doi = {10.34141/ljcs1446110}
}
EUVIMED